http://www.gosreports.com
Hepatitis D – Pipeline Review 2021 by Gosreports forecast
Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.
Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Hepatitis D – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Full Report:
http://www.gosreports.com/global-residential-air-purifiers-market-research-report-2016/
The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 5, 4 and 2 respectively for Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively for Hepatitis D.
Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Table of contents:
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hepatitis D Overview 7
Therapeutics Development 8
Pipeline Products for Hepatitis D – Overview 8
Pipeline Products for Hepatitis D – Comparative Analysis 9
Hepatitis D – Therapeutics under Development by Companies 10
Hepatitis D – Therapeutics under Investigation by Universities/Institutes 11
Hepatitis D – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hepatitis D – Products under Development by Companies 15
Hepatitis D – Products under Investigation by Universities/Institutes 16
Hepatitis D – Companies Involved in Therapeutics Development 17
Alnylam Pharmaceuticals, Inc. 17
Arrowhead Pharmaceuticals, Inc. 18
Eiger BioPharmaceuticals, Inc. 19
F. Hoffmann-La Roche Ltd. 20
Globeimmune, Inc. 21
REPLICor Inc. 22
Rodos BioTarget GmbH 23
SomaGenics, Inc. 24
Spring Bank Pharmaceuticals, Inc. 25
Hepatitis D – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
ALN-HDV – Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ARC-520 – Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
GI-18000 – Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
lonafarnib – Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Myrcludex-B – Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
peginterferon alfa-2a – Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
peginterferon lambda-1a – Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
RBT-05 – Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
REP-2139 – Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
REP-2165 – Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
RNAi Oligonucleotide for Hepatitis D – Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
SB-9200 – Drug Profile 61
Product Description 61
……………………
More Information:
http://www.gosreports.com/global-residential-air-purifiers-market-research-report-2016/
http://www.gosreports.com/global-lie-detector-market-research-report-2016/

Contacts Us
Joanna | Executive - International Business and partner Relations
E-mail: [email protected] 
Tel: 001-510-400-8520
Web: www.gosreports.com